AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)
31.28 USD
+0.010 0.032%Sponsored Reports
Loading...
| Previous Close (in USD) | 31.27 |
|---|---|
| Change | +0.010 0.032% |
| 52 W H/L (in USD) | 26.580/19.050 |
| EBITDA (in USD) | 295.651M |
| PE Ratio | 15.54 |
| Volume | 1682058 |
| Diluted Eps TTM | 1.65 |
| Total Assets (in USD) | 1106.811M |
|---|---|
| Total Liabilities (in USD) | 152.543M |
| Revenue TTM (in USD) | 588.989M |
| Cash (in USD) | 709.171M |
| Market Cap (in USD) | 3,151.473 M |
| Revenue Per Share TTM | 4.816 |
| Gross Profit TTM (in USD) | 489.027M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Employees: 182
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Patrick J. McEnany | Co-Founder, Chairman, Pres & CEO | 1947 |
| 2. | Ms. Alicia Grande C.M.A., CPA, CMA, CPA | Chief Accounting Officer, VP, Treasurer & CFO | 1971 |
| 3. | Dr. Steven R. Miller Ph.D. | COO & Chief Scientific Officer | 1962 |
| 4. | Dr. Gary Ingenito M.D., Ph.D. | Chief Medical & Regulatory Officer | 1956 |
| 5. | Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer | 1976 |
| 6. | Ms. Mary Coleman | VP & Head of Investor Relations | NA |
| 7. | Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | 1964 |
| 8. | Mr. Pete Curry Sr. | VP of Sales | NA |
| 9. | Mr. Jeffrey Del Carmen | Chief Commercial Officer | 1971 |
| 10. | Mr. Philip B. Schwartz | Corp. Sec. | 1955 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | 283.515M | 216.263M | 94.511M | 104.719M | 52.667M |
| Minority Interest | - | - | - | - | - |
| Net Income | 214.326M | 163.889M | 71.41M | 83.079M | 39.482M |
| Selling General Administrative | 193.751M | 167.74M | 47.021M | 28.714M | 23.477M |
| Gross Profit | 501.736M | 422.889M | 346.237M | 179.81M | 118.949M |
| Reconciled Depreciation | 37.873M | 37.774M | 24.353M | 1.239M | 0.192M |
| Ebit | 283.515M | 195.124M | 86.812M | 100.599M | 52.193M |
| Ebitda | 321.013M | 232.898M | 119.693M | 101.838M | 52.385M |
| Depreciation And Amortization | 37.498M | 37.774M | 32.881M | 1.239M | 0.192M |
| Operating Income | 257.778M | 195.124M | 86.812M | 101.838M | 52.385M |
| Other Operating Expenses | 331.211M | 296.61M | 311.392M | 112.365M | 88.448M |
| Interest Expense | - | - | - | -4.12M | 0.474M |
| Tax Provision | 69.189M | 52.374M | 18.775M | 21.64M | 13.185M |
| Interest Income | - | - | - | - | - |
| Net Interest Income | 24.765M | 16.064M | 4.675M | - | - |
| Income Tax Expense | 69.189M | 52.374M | 23.101M | 21.64M | 13.185M |
| Total Revenue | 588.989M | 491.734M | 398.204M | 214.203M | 140.833M |
| Total Operating Expenses | 243.958M | 227.765M | 259.425M | 77.972M | 66.564M |
| Cost Of Revenue | 87.253M | 68.845M | 51.967M | 34.393M | 21.884M |
| Total Other Income Expense Net | 25.737M | 21.139M | 7.699M | 2.881M | 0.282M |
| Net Income From Continuing Ops | 214.326M | 163.889M | 62.037M | 83.079M | 39.482M |
| Net Income Applicable To Common Shares | - | - | - | 83.079M | 39.482M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 1106.811M | 851.411M | 471.907M | 375.63M | 237.788M |
| Intangible Assets | 131.674M | 156.672M | 194.049M | 32.471M | - |
| Other Current Assets | 19.427M | 21.028M | 12.535M | 5.158M | 4.351M |
| Total Liab | 152.543M | 123.779M | 84.026M | 75.209M | 30.957M |
| Total Stockholder Equity | 954.268M | 727.632M | 387.881M | 300.421M | 206.831M |
| Other Current Liab | 135.513M | 102.789M | 60.17M | 53.276M | 0.243M |
| Common Stock | 0.123M | 0.121M | 0.107M | 0.105M | 0.103M |
| Capital Stock | 0.123M | 0.121M | 0.107M | 0.105M | 0.103M |
| Retained Earnings | 474.188M | 285.161M | 121.272M | 49.862M | -26.31M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0M | 18.745M | 23.706M |
| Cash | 709.171M | 517.553M | 137.636M | 298.395M | 171.445M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 147.152M | 120.678M | 76.063M | 57.588M | 27.063M |
| Current Deferred Revenue | - | - | 0.729M | - | 23.744M |
| Net Debt | -706.384M | -514.365M | -134.079M | -294.501M | -167.551M |
| Short Term Debt | 0.437M | 0.402M | 0.369M | 0.337M | 0.308M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 2.787M | 3.188M | 3.557M | 3.894M | 3.894M |
| Other Stockholder Equity | 479.957M | 442.286M | 266.488M | 250.43M | 233.186M |
| Property Plant Equipment | - | - | - | 0.847M | 3.976M |
| Total Current Assets | 894.03M | 623.609M | 219.329M | 320.797M | 210.106M |
| Long Term Investments | 22.536M | 21.564M | 16.489M | - | - |
| Short Term Investments | - | - | - | 0M | 19.821M |
| Net Receivables | 128.266M | 65.487M | 53.514M | 10.439M | 6.619M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 37.166M | 19.541M | 15.644M | 6.805M | 7.87M |
| Accounts Payable | 11.202M | 16.593M | 14.795M | 3.975M | 2.768M |
| Accumulated Other Comprehensive Income | - | 0.064M | 0.014M | 0.024M | -0.148M |
| Non Currrent Assets Other | - | - | -0M | 0.009M | 0.009M |
| Non Current Assets Total | 212.781M | 227.802M | 252.578M | 54.833M | 27.682M |
| Capital Lease Obligations | 2.787M | 3.188M | 3.557M | 3.894M | 3.894M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 0M | -0.556M | -255.184M | 19.238M | -10M |
| Total Cashflows From Investing Activities | -0.058M | -0.556M | - | 9.209M | -11.021M |
| Total Cash From Financing Activities | -16.994M | 140.665M | -10.857M | 1.694M | -8.143M |
| Net Income | 214.326M | 163.889M | 71.41M | 83.079M | 39.482M |
| Change In Cash | 191.618M | 379.917M | -160.759M | 126.95M | 41.208M |
| Begin Period Cash Flow | 517.553M | 137.636M | 298.395M | 171.445M | 130.237M |
| End Period Cash Flow | 709.171M | 517.553M | 137.636M | 298.395M | 171.445M |
| Total Cash From Operating Activities | 208.67M | 239.808M | 143.6M | 116.047M | 60.372M |
| Depreciation | 37.873M | 37.774M | 33.143M | 1.239M | 0.192M |
| Other Cashflows From Investing Activities | - | 13.14M | - | -10M | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -18.089M | -3.897M | -4.739M | 1.065M | -3.219M |
| Sale Purchase Of Stock | -25.3M | -0.296M | -0.982M | -6.907M | -12.089M |
| Other Cashflows From Financing Activities | -6.363M | -0.039M | -13.649M | 4.502M | -0.153M |
| Capital Expenditures | 0.058M | 0.556M | 198.524M | 0.029M | 1.021M |
| Change In Working Capital | -60.895M | 30.914M | -37.324M | 13.729M | 5.022M |
| Other Non Cash Items | -0.563M | -5.632M | 79.939M | 5.156M | 0.287M |
| Free Cash Flow | 208.612M | 239.252M | -54.924M | 116.018M | 59.351M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Avantis US Small Cap Value ETF | 2 months ago | 3373888 |
| 2. | Smithson Investment Trust Ord | 6 months ago | 3363807 |
| 3. | Oberweis Micro-Cap Growth | 2 months ago | 690300 |
| 4. | iShares Core S&P Small-Cap ETF | 2 months ago | 6938748 |
| 5. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 3713037 |
| 6. | iShares Russell 2000 ETF | 2 months ago | 2813053 |
| 7. | State Street® SPDR® S&P® Biotech ETF | 2 months ago | 2373592 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 1288666 |
| 9. | Janus Henderson Hrzn Glb SC E2 USD | 3 months ago | 1128556 |
| 10. | Fidelity Small Cap Index | 4 months ago | 1118413 |
| 11. | State Street SPDR Port S&P 600 Sm CpETF | 2 months ago | 1044702 |
| 12. | iShares S&P Small-Cap 600 Growth ETF | 2 months ago | 996824 |
| 13. | iShares Russell 2000 Growth ETF | 2 months ago | 943063 |
| 14. | Kennedy Small Cap Value | 2 months ago | 872103 |
| 15. | Vanguard Tax-Managed Small Cap Adm | 2 months ago | 746249 |
| 16. | Russell 2000 Equity Index Fund B | 5 months ago | 721226 |
| 17. | State St Russell Sm/Mid Cp® Indx SL Cl I | 2 months ago | 688998 |
| 18. | State Street® SPDR® S&P 600™ Sm Cp GrETF | 2 months ago | 609474 |
| 19. | Fidelity Extended Market Index | 3 months ago | 603200 |
| 20. | Royce Small-Cap Trust | 2 months ago | 599279 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | American Century Companies Inc | 5 months ago | 3025271 |
| 2. | Dimensional Fund Advisors, Inc. | 5 months ago | 2996297 |
| 3. | Geode Capital Management, LLC | 5 months ago | 2900337 |
| 4. | Renaissance Technologies Corp | 5 months ago | 2650077 |
| 5. | Bank of America Corp | 8 months ago | 2291414 |
| 6. | Royce & Associates, LP | 5 months ago | 1910767 |
| 7. | Morgan Stanley - Brokerage Accounts | 8 months ago | 1843624 |
| 8. | Arrowstreet Capital Limited Partnership | 5 months ago | 1617208 |
| 9. | Charles Schwab Investment Management Inc | 5 months ago | 1356499 |
| 10. | BlackRock Inc | 8 months ago | 18216060 |
| 11. | Vanguard Group Inc | 5 months ago | 8432247 |
| 12. | State Street Corp | 8 months ago | 6405387 |
| 13. | Deerfield Management Co | 5 months ago | 4911161 |
| 14. | Fundsmith LLP | 5 months ago | 3363807 |
| 15. | Northern Trust Corp | 8 months ago | 1263888 |
| 16. | Amvescap Plc. | 8 months ago | 1233257 |
| 17. | Boston Partners Global Investors, Inc | 5 months ago | 1231372 |
| 18. | Kennedy Capital Management Inc | 5 months ago | 1209692 |
| 19. | Millennium Management LLC | 5 months ago | 993647 |
| 20. | The Goldman Sachs Group Inc | 5 months ago | 979543 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...